Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Perspectives

  3. Advancing diagnosis and follow-up together
Neurology

Advancing diagnosis and follow-up together

Given the limited therapeutic options for neurodegenerative diseases, researchers and industry are pooling their strengths to accelerate progress in diagnosis and treatment.

3min
Doris Pischitz
Published on January 5, 2022

Laboratory diagnostics is a promising field that could help physicians arrive at an earlier diagnosis and facilitate monitoring and follow-up during treatment.

The role of neurofilament light in neuronal damage

NfL is released when neuronal damage occurs.

Focus on multiple sclerosis

A patient receives an infusion.

From invasive lumbar puncture to a simple blood draw

Interior views of the Center for Innovation in Diagnostics, run by Siemens Healthineers, with laboratorians working on the systems.

The Center for Innovation in Diagnostics CLIA laboratory in Berkeley, California, offers state-of-the-art biomarker diagnostic test development, and testing services for therapy development programs.

Toward treatment

By Doris Pischitz
Doris Pischitz is an editor in corporate communications at Siemens Healthineers. The team specializes in topics related to healthcare, medical technology, disease areas, and digitalization.

Discover more

Neurology

Zooming in on the brain’s microarchitecture
  1. 1 NfL is currently not for sale for diagnostic purpose. The NfL assay testing service is available from Siemens Healthcare Laboratory in Berkeley, California.
  2. 2 The product/feature and/or service offerings (mentioned herein) are not commercially available in all countries and/or for all modalities. Their future availability cannot be guaranteed.
  3. [1] Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954–963.
  4. [2] Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870–881.
  5. [3] Susuki K. Myelin: A Specialized Membrane for Cell Communication. Nature Education. 2010;3(9):59.
  6. [4] Manouchehrinia A, Stridh P, Khademi M, Leppert D, Barro C, Michalak Z, et al. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology. 2020;94(23):e2457–e2467.
  7. [5] Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007–e1015.
  1. The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.